Tectonic Therapeutic, Inc. (TECX) company profile

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors. Using its proprietary GEODe technology platform, the company creates biologics for conditions with substantial unmet medical needs. Its primary drug candidates include TX45, an Fc-relaxin fusion protein in clinical trials for pulmonary hypertension related to heart failure and interstitial lung disease, and TX2100, an antibody targeting the apelin receptor for the treatment of hereditary hemorrhagic telangiectasia. Because its candidates are in clinical and preclinical development, the company currently serves patient populations participating in clinical research rather than commercial customers.

The company operates from leased office and laboratory facilities and conducts research and clinical development activities across several countries, including the United States, Australia, and Canada. Tectonic Therapeutic is incorporated in Delaware and maintains its principal executive offices and headquarters in Watertown, Massachusetts.

Summary of the business section of Tectonic Therapeutic's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“PER SHARE TOTAL Public Offering Price $19.00 $99,711,202 Underwriting Discounts and Commissions (1) 1.33 6,979,784 Proceeds to us, before expenses 17.67 92,731,418 (1) See “Underwriters” in this prospectus for a description of compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 60 full-time employees, 48 of whom were primarily engaged in research and development activities, and 26 of our employees had an M.D.”